申请人:Mitsubishi Pharma Corporation
公开号:US06468998B1
公开(公告)日:2002-10-22
The present invention provides a pyrrolidine compound of the formula (I)
wherein each symbol is as defined in the specification, an optically active compound thereof and a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition containing a compound of the formula (I), an optically active compound thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. The compound of the present invention has a serotonin 2 receptor antagonistic action along with a platelet aggregation suppressive action, a peripheral circulation improving action and a lacrimation promoting action. Therefore, the compound of the present invention can be a useful medicine showing effect against thrombotic embolism, dry eye and the like.
本发明提供了一种式(I)的吡咯烷化合物,其中每个符号如规范中定义,以及其光学活性化合物和药学上可接受的盐。本发明还提供了一种含有式(I)的化合物、其光学活性化合物或药学上可接受的盐以及药学上可接受的添加剂的药物组合物。本发明的化合物具有血清素2受体拮抗作用,同时具有抑制血小板聚集、改善外周循环和促进泪液分泌的作用。因此,本发明的化合物可以是一种有益的药物,对抗血栓栓塞、干眼症等具有一定效果。